{"protocolSection":{"identificationModule":{"nctId":"NCT04817527","orgStudyIdInfo":{"id":"XJTU1AF2021LSK-065"},"organization":{"fullName":"First Affiliated Hospital Xi'an Jiaotong University","class":"OTHER"},"briefTitle":"Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows","officialTitle":"Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows (EXISTENT):a Prospective, Randomized, Open-label, Multi-centre Study","acronym":"EXISTENT"},"statusModule":{"statusVerifiedDate":"2021-08","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-10-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-12-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2022-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-03-25","studyFirstSubmitQcDate":"2021-03-25","studyFirstPostDateStruct":{"date":"2021-03-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-03-30","lastUpdatePostDateStruct":{"date":"2022-04-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"First Affiliated Hospital Xi'an Jiaotong University","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To explore the safety and efficacy of edaravone dexborneol for patients of acute ischemic stroke received endovascular therapy in extended time windows."},"conditionsModule":{"conditions":["Stroke, Ischemic"],"keywords":["Endovascular therapy","Extended Time Windows"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":200,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Edaravone Dexborneol","type":"EXPERIMENTAL","interventionNames":["Drug: Edaravone Dexborneol"]},{"label":"conventional therapy","type":"NO_INTERVENTION","description":"conventional therapy of acute ischemic stroke after Endovascular Therapy based on Chinese guidelines for endovascular therapy"}],"interventions":[{"type":"DRUG","name":"Edaravone Dexborneol","description":"Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.","armGroupLabels":["Edaravone Dexborneol"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of patients with modified Rankin Score 0 to 3 on day 90","timeFrame":"90 days"},{"measure":"Proportion of symptomatic intracranial hemorrhage (sICH)","timeFrame":"48 hours"},{"measure":"mTICI grade (<2 b、≥2 b) stratified for primary outcome analysis","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"Changes in National Institute of Health stroke scale (NIHSS) on day 2,7,14","timeFrame":"14 days"},{"measure":"Distribution of modified Rankin Score after the treatment","timeFrame":"90 days"},{"measure":"Change in infarct volume","timeFrame":"7 days"},{"measure":"The proportion of patients with Barthel Index (BI) score greater than or equal to 95 on day 14, 30, 90","timeFrame":"90 days"},{"measure":"Activity of Daily Living Scale(ADL) score on day 14, 30, 90","timeFrame":"90 days"},{"measure":"Montreal Cognitive Assessment(MoCA) score on day 14, 30, 90","timeFrame":"90 days"},{"measure":"Serum inflammatory factors changes on day 1 and day 7","timeFrame":"7 days"},{"measure":"Proportion of PH1 and PH2 within 48 hours after the treatment","timeFrame":"48 hours"},{"measure":"Midline shift on the CT scan","timeFrame":"7 days"},{"measure":"Proportion of death due to any cause","timeFrame":"90 days"},{"measure":"Proportion of Serious adverse events(SAE)","timeFrame":"90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. 18 to 80 years of age;\n2. Acute ischemic stroke with National Institute of Health Stroke Scale (NIHSS) ≥ 10 and Volume of infarction on DWI \\<31ml or with a NIHSS ≥20 and 31ml\\<Volume of infarction\\<51ml(DWI);\n3. Patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation;\n4. Endovascular Therapy in 6-24 hours of stroke onset;\n5. The availability of informed consent.\n\nExclusion Criteria:\n\n1. First ever stroke or mRS≤1 after previous disease;\n2. Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;\n3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia\n4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n5. Severe cardiac or pulmonary disease;\n6. Patients with malignant tumor or under antineoplastic therapy with estimated lifetime less than 3 months;\n7. Pregnancy, plan to get pregnant or during lactation;\n8. Patients with contraindication or allergic to any ingredient of drugs in our study;\n9. Unsuitable for this clinical studies assessed by researcher","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Jianfeng Han, MD","role":"CONTACT","phone":"+8618991232708","email":"rabbit1110@163.com"},{"name":"Ying Tan, MD","role":"CONTACT","phone":"+8613581693768","email":"13581693768@163.com"}],"locations":[{"facility":"First Affiliated Hospital of Xian Jiaotong University","status":"RECRUITING","city":"Xi'an","state":"Shaanxi","zip":"710061","country":"China","contacts":[{"name":"Jianfeng Han, MD","role":"CONTACT"}],"geoPoint":{"lat":34.25833,"lon":108.92861}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077553","term":"Edaravone"}],"ancestors":[{"id":"D000016166","term":"Free Radical Scavengers"},{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M1831","name":"Edaravone","asFound":"Lay","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}